Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine in Reducing Postoperative Delirium in Cardiac Surgery Patients
NCT06619912Phase 3Completed
- Sponsor
- Xijing Hospital
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in postoperative delirium (POD) (2 arms), sponsored by Xijing Hospital. Primary endpoint: Postoperative delirium occurrence at 1 week. Started Mar 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT06619912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619912.